文献速递消化系统肿瘤

图卡替尼联合曲妥珠单抗治疗化疗难治性HER2阳性RAS野生型不可切除或转移性结直肠癌(MOUNTAINEER):多中心、开放标签、2期研究

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
PubMed 文献 · Lancet Oncol · 2023-01-01

MOUNTAINEER研究是一项全球多中心开放标签2期研究,评估图卡替尼联合曲妥珠单抗在化疗难治性HER2阳性RAS野生型不可切除或转移性结直肠癌患者中的活性。全分析集中队列A和B的确认客观缓解率(BICR)为38.1%(95%CI 27.7-49.3)。该方案具有临床意义的抗肿瘤活性和良好的耐受性。

要点

  • 图卡替尼联合曲妥珠单抗在化疗难治性HER2阳性RAS野生型转移性结直肠癌中确认客观缓解率为38.1%。
  • 队列A和B中最常见不良事件为腹泻(64%),最常见≥3级不良事件为高血压(7%)。
  • 该方案是美国FDA批准的首个用于转移性结直肠癌的抗HER2方案。

核心结论

  • 图卡替尼联合曲妥珠单抗具有临床意义的抗肿瘤活性和良好的耐受性。
  • 该治疗是美国食品药品监督管理局批准的首个用于转移性结直肠癌的抗HER2方案,是化疗难治性HER2阳性转移性结直肠癌的重要新治疗选择。

研究设计与样本

  • MOUNTAINEER是一项全球、开放标签、2期研究,在5个国家(比利时、法国、意大利、西班牙和美国)的34个中心(诊所和医院)入组患者。
  • 入组患者为18岁及以上、化疗难治性、HER2阳性、RAS野生型不可切除或转移性结直肠癌患者。
  • 研究初始设计为单队列研究,中期分析后扩展纳入更多患者;初始患者接受图卡替尼(300 mg口服每日两次)联合静脉曲妥珠单抗(初始负荷剂量8 mg/kg,之后每21天6 mg/kg;队列A)治疗至进展。
  • 扩展后,患者按4:3随机分配至图卡替尼联合曲妥珠单抗(队列B)或图卡替尼单药(队列C),使用交互式网络应答系统并按原发肿瘤部位分层。
  • 主要终点为队列A和B合并的盲态独立中心审查(BICR)确认客观缓解率,在全分析集(即接受至少一剂研究治疗的HER2阳性患者)中评估。

主要发现

  • 2017年8月8日至2021年9月22日期间,共入组117例患者(队列A 45例,队列B 41例,队列C 31例),其中114例患者为局部评估HER2阳性并接受治疗(队列A 45例,队列B 39例,队列C 30例;全分析集),116例患者接受至少一剂研究治疗(队列A 45例,队列B 41例,队列C 30例;安全性人群)。
  • 全分析集中位年龄为56.0岁(IQR 47-64),男性66例(58%),女性48例(42%),白人88例(77%),黑人或非裔美国人6例(5%)。
  • 截至数据截止日(2022年3月28日),全分析集中队列A和B共84例患者,BICR确认客观缓解率为38.1%(95%CI 27.7-49.3;3例完全缓解,29例部分缓解)。
  • 队列A和B中,最常见不良事件为腹泻(86例中55例[64%]),最常见≥3级不良事件为高血压(86例中6例[7%]),3例(3%)患者发生图卡替尼相关严重不良事件(急性肾损伤、结肠炎和乏力)。
  • 队列C中,最常见不良事件为腹泻(30例中10例[33%]),最常见≥3级不良事件为丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高(各2例[7%]),1例(3%)患者发生图卡替尼相关严重不良事件(药物过量);无不良事件导致的死亡,所有治疗患者死亡均因疾病进展。

关键数值与推荐

  • 全分析集中队列A和B的BICR确认客观缓解率为38.1%(95%CI 27.7-49.3)。
  • 队列A和B中图卡替尼相关严重不良事件发生率为3%(3例)。
  • 队列C中图卡替尼相关严重不良事件发生率为3%(1例)。

临床怎么用

  • 原文结论指出图卡替尼联合曲妥珠单抗是化疗难治性HER2阳性转移性结直肠癌的重要新治疗选择,且为美国FDA批准的首个用于转移性结直肠癌的抗HER2方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HER2 is an actionable target in metastatic colorectal cancer. We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. METHODS: MOUNTAINEER is a global, open-label, phase 2 study that enrolled patients aged 18 years and older with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer at 34 sites (clinics and hospitals) in five countries (Belgium, France, Italy, Spain, and the USA). Initially, the study was designed as a single-cohort study, which was expanded following an interim analysis to include more patients. Initially, patients were given tucatinib (300 mg orally twice daily) plus intravenous trastuzumab (8 mg/kg as an initial loading dose, then 6 mg/kg every 21 days; cohort A) for the duration of treatment (until progression), and after expansion, patients were randomly assigned (4:3), using an interactive web response system and stratified by primary tumour location, to either tucatinib plus trastuzumab (cohort B) or tucatinib monotherapy (cohort C). The primary endpoint was confirmed objective response rate per blinded independent central review (BICR) for cohorts A and B combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disease who received at least one dose of study treatment). Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT03043313, and is ongoing. FINDINGS: Between Aug 8, 2017, and Sept 22, 2021, 117 patients were enrolled (45 in cohort A, 41 in cohort B, and 31 in cohort C), of whom 114 patients had locally assessed HER2-positive disease and received treatment (45 in cohort A, 39 in cohort B, and 30 in cohort C; full analysis set), and 116 patients received at least one dose of study treatment (45 in cohort A, 41 in cohort B, and 30 in cohort C; safety population). In the full analysis set, median age was 56·0 years (IQR 47-64), 66 (58%) were male, 48 (42%) were female, 88 (77%) were White, and six (5%) were Black or African American. As of data cutoff (March 28, 2022), in 84 patients from cohorts A and B in the full analysis set, the confirmed objective response rate per BICR was 38·1% (95% CI 27·7-49·3; three patients had a complete response and 29 had a partial response). In cohorts A and B, the most common adverse event was diarrhoea (55 [64%] of 86), the most common grade 3 or worse adverse event was hypertension (six [7%] of 86), and three (3%) patients had tucatinib-related serious adverse events (acute kidney injury, colitis, and fatigue). In cohort C, the most common adverse event was diarrhoea (ten [33%] of 30), the most common grade 3 or worse adverse events were increased alanine aminotransferase and aspartate aminotransferase (both two [7%]), and one (3%) patient had a tucatinib-related serious adverse event (overdose). No deaths were attributed to adverse events. All deaths in treated patients were due to disease progression. INTERPRETATION: Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer. FUNDING: Seagen and Merck & Co.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023. PMID: 37142372. doi:10.1016/S1470-2045(23)00150-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。